MedTrace Logo

Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)

NCT00738972 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-08-26

Study results available
· View outcomes & findings →

Summary

Evaluate pleiotropic effects of simvastatin in hypertensive patients.

Conditions

Interventions

DRUG

valsartan

80 mg valsartan. Duration: 12 months. Tablets

DRUG

pravastatin

40 mg pravastatin. Duration: 12 months. Tablets

DRUG

simvastatin

40 mg simvastatin. Duration: 12 months. Tablets

DRUG

ezetimibe (+) simvastatin

ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets

Sponsors & Collaborators

  • Fundación Lindavista del Corazón AC

    lead OTHER

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-08-31
Completion
2010-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00738972 on ClinicalTrials.gov